Proteomics-Based Comparative Mapping of the Secretomes of Human Brown and White Adipocytes Reveals EPDR1 as a Novel Batokine

Highlights
- Identification of the first human brown fat secretome
- Comparative analysis of the secretomes of human brown and white adipocytes
- 101 proteins were exclusively identified in the secretome of brown adipocytes
- EPDR1 is a novel batokine important for brown fat commitment

Authors
Atul S. Deshmukh, Lone Peijs, Jacqueline L. Beaudry, ..., Daniel J. Drucker, Matthias Mann, Camilla Scheele

Correspondence
matthias.mann@cpr.ku.dk (M.M.), cs@sund.ku.dk (C.S.)

In Brief
Deshmukh et al. describe the human brown fat secretome and identify novel candidate batokines with potential effects on human metabolism. One such batokine is EPDR1, shown here to play a role in brown fat commitment.
Proteomics-Based Comparative Mapping of the Secretomes of Human Brown and White Adipocytes Reveals EPDR1 as a Novel Batokine


1Department of Proteomics and Signal Transduction, Max-Planck-Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany
2The Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark
3Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark
4The Centre of Inflammation and Metabolism and the Centre for Physical Activity Research, Rigshospitalet, University of Copenhagen, Copenhagen 2100, Denmark
5The Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Department of Medicine, University of Toronto, Toronto, ON M5G 1X5, Canada
6Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen 2200, Denmark
7Minerva Imaging ApS, Copenhagen 2200, Denmark
8Laboratory of Molecular Medicine, Department of Clinical Immunology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen 2100, Denmark
9Global Drug Discovery, Novo Nordisk A/S, Måløv 2760, Denmark
10Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark
11Princess Margaret Cancer Centre, Toronto, ON M5G 1L7, Canada
12These authors contributed equally
13Senior author
14Lead Contact
*Correspondence: matthias.mann@cpr.ku.dk (M.M.), cs@sund.ku.dk (C.S.)

https://doi.org/10.1016/j.cmet.2019.10.001

SUMMARY

Adipokines secreted from white adipose tissue play a role in metabolic crosstalk and homeostasis, whereas the brown adipose secretome is less explored. We performed high-sensitivity mass-spectrometry-based proteomics on the cell media of human adipocytes derived from the supraclavicular brown adipose and from the subcutaneous white adipose depots of adult humans. We identified 471 potentially secreted proteins covering interesting categories such as hormones, growth factors, extracellular matrix proteins, and proteins of the complement system, which were differentially regulated between brown and white adipocytes. A total of 101 proteins were exclusively quantified in brown adipocytes, and among these was ependymin-related protein 1 (EPDR1). EPDR1 was detected in human plasma, and functional studies suggested a role for EPDR1 in thermogenic determination during adipogenesis. In conclusion, we report substantial differences between the secretomes of brown and white human adipocytes and identify novel candidate batokines that can be important regulators of human metabolism.

Context and Significance

In this paper, researchers from the University of Copenhagen focused on identifying the entire spectrum (or “secretome”) of proteins released by human white adipocytes and the heat-producing and energy-burning brown adipocytes. The authors found a substantial difference in the secretomes; for example, indicating a higher anti-inflammatory capacity in brown adipocytes and a higher ability of plasticity in white adipocytes. 101 proteins were exclusively quantified in the secretome of brown adipocytes. One of these proteins was EPDR1, which was found to be important for brown fat cell development. This study further provides a catalog of molecules that could be involved in regulating human metabolism, and possibly leading to the discovery of novel drug targets for obesity and its associated diseases.
INTRODUCTION

Adipose tissue is a major regulator of whole-body energy homeostasis by communication with the brain and other organs (Stem et al., 2016). Well-established mediators of adipocyte-derived crosstalk include leptin and adiponectin, which are produced and secreted by white adipose tissue (WAT) and contribute to the regulation of whole-body energy homeostasis (Ahima et al., 1996; Scherer et al., 1999). Adipokines derived from brown adipose tissue (BAT), known as batokines (Villarroya et al., 2017), are less investigated, especially in humans. BAT differs from WAT in its heat-producing capacity, providing an energy-consuming process, which is turned on or off in response to sympathetic activation (Cannon and Nedergaard, 2004). Considering the functional differences in WAT and BAT, batokines represent a poorly explored source of metabolic regulators. Some of the identified batokines have been described as having a hormonal function, enhancing BAT activity, improving glucose metabolism, or mediating browning of white fat (Lee et al., 2014; Stanford et al., 2013; Svensson et al., 2016). Batokines could also be represented by growth factors acting in an autocrine or paracrine manner by regulating BAT differentiation (Villarroya et al., 2017). Mapping of the human BAT secretome has previously been restricted by the lack of representative human BAT cell models as well as the challenges associated with measuring the secretome in cell culture media. However, the development of advanced secretomics technology as well as non-immortalized human BAT cell models has now made such experiments possible (Deshmukh et al., 2015; Jespersen et al., 2013; Meissner et al., 2013). In the current study, we investigated the secretomes of human brown and white adipocytes using high-resolution mass spectrometry (MS)-based proteomics. We mine the results for novel candidates with the potential for intercellular communication and perform follow up studies on Mammalian ependymin-related protein 1 (EPDR1), shown here to be a modulator of energy homeostasis and thermogenic commitment.

RESULTS AND DISCUSSION

The Secretome of Human Brown and White Adipocytes

Supraclavicular fat precursor cells (termed brown throughout this manuscript) were derived from five adult humans, as previously reported (Jespersen et al., 2013). The cell cultures were matched with subcutaneous fat precursor cells (termed white throughout this manuscript) with equal differentiation capacity throughout this manuscript) with equal differentiation capacity. Cell culture media. However, the development of advanced secretomics technology as well as non-immortalized human BAT cell models has now made such experiments possible (Deshmukh et al., 2015; Jespersen et al., 2013; Meissner et al., 2013). In the current study, we investigated the secretomes of human brown and white adipocytes using high-resolution mass spectrometry (MS)-based proteomics. We mine the results for novel candidates with the potential for intercellular communication and perform follow up studies on Mammalian ependymin-related protein 1 (EPDR1), shown here to be a modulator of energy homeostasis and thermogenic commitment.

Comparative Mapping of Human Brown versus White Adipocyte Secretomes

We applied label-free quantification based on the MaxLFQ algorithm, which has proven robust and allows a comparison of an arbitrary number of samples simultaneously (Cox et al., 2014). The secretomes were highly correlated within groups (median Pearson correlation for the brown adipocytes = 0.86; Figure 2A; Table S1). The secretomes of brown and white adipocytes were sufficiently separated to classify them as distinct entities as visualized by a principal component analysis (PCA) (Figure 2B). In our search for novel batokines, we filtered for proteins that were annotated with gene ontologies (GOs) for growth factor activity or hormone activity. This identified six hormones (Figure 2C) and eight growth factors (Figure 2D; Table S2). We calculated the fold change for these proteins between unstimulated brown and white adipocytes (woNE brown/white), unstimulated and NE-stimulated brown adipocytes (brown NE/woNE), and unstimulated and NE-stimulated white adipocytes (white NE/woNE). Among the hormones was the well-described adipokine adiponectin (ADIPOQ) (Scherer et al., 1995; Stern et al., 2016), while VEGF-A is a growth factor previously reported as one of the most studied white fat-derived hormones (Jespersen et al., 2013), while VEGF-A is a growth factor previously reported as important for the development of functional BAT (Park et al., 2017; Shimizu et al., 2014). The presence of a signal peptide suggests secretion through the classical ER-Golgi pathway, yet hundreds of intracellular proteins are thought to be secreted through various non-classical pathways, including secretion from exosomes and microvesicles (Huberts and van der Klei, 2010; Nickel and Rabouille, 2009). Mapping of our dataset with Vesiclepedia (Kalra et al., 2012) and ExoCarta (Keerthikumar et al., 2016) revealed that almost all proteins overlapped with secreted proteins found in these two databases (Figure 1I).
Figure 1. Model and Proteomics Workflow for Generating the Secretome of Human Brown and White Adipocytes

(A and B) (A) Mature adipocytes (brown adipocytes from n = 5 human donors; white adipocytes from n = 5 human donors) included in the study were characterized for (B) lipid droplet accumulation (estimated visually by phase contrast microscopy).
(HDGF) were more abundant in the brown adipocyte media than the white adipocyte media and could be considered as potential batokines. Granulins are cleaved into nine chains and have been described as autocrine growth factors important for wound healing (He et al., 2003). Granulins have not previously been described as batokines. However, one of the nine chains, acrogranin, also known as progranulin, was identified as a WAT-derived adipokine mediating high-fat diet (HFD)-induced insulin resistance in mice (Matsubara et al., 2012) and circulating levels of PRGN is associated with systemic insulin sensitivity in patients with metabolic syndrome (Li et al., 2014). HDGF promotes mitogenic activity through DNA-binding mediated transcriptional repression (Yang and Everett, 2007) but has also been detected in the extracellular region (Nüße et al., 2017). Taken together, our secretome analyses identified both established adipokines and novel candidate batokines and adipokines.

When comparing NE-induced secretomes in both brown and white adipocytes, we surprisingly observed many ribosomal proteins or proteins involved in translational processes (Table S2). We therefore decided to focus on the proteins secreted from brown and white adipocytes without norepinephrine stimulation in our search for novel batokines. A PCA plot including all proteins quantified under non-stimulated conditions revealed a clear separation between brown and white adipocytes (Figure 2E). A two-sample t test returned 143 differentially regulated proteins of which 106 were more abundant in cell media from brown adipocytes, while 37 were more abundant in cell media from white adipocytes (Figures 2F and 2G; Table S2). Fischer exact test (FDR = 0.02) for enrichment on significantly different protein in the background of total quantified proteins (1,113) returned only two categories: “Extracellular (GOCC)” and “secreted (UniProt Keyword).” This analysis suggests that the majority of differentially regulated proteins in brown and white adipocyte cell culture media are truly secreted proteins (Figure 2G). Several white-adipocyte-selective secreted proteins were extracellular matrix (ECM) associated, including transforming growth factor beta 1 (TGFβ1), which has been associated with diabetes risk (Kim et al., 2013), and tenascin (TNC), an ECM glycoprotein with proinflammatory effects, which is highly expressed in WAT of obese patients and in murine models of obesity (Kim et al., 2013). We observed a more than 2-fold higher secretion of TNC and COL18A1 in cell media from brown adipocytes compared to white adipocytes (Table S2) and have been shown to be involved in proliferation and regulation of immune function (Hannappel and Huff, 2003; Samara et al., 2017). The biological role of PTMS and PTMA in brown fat has not been explored. Although these proteins are not annotated as secreted, it is possible that they are secreted via exosomes or microvesicles from brown adipocytes. Interestingly, the clathrin-related proteins CLTA and CLTB, coating proteins of intracellular vesicles (Pearse, 1976), were also among the proteins with higher abundance in cell media from brown adipocytes compared to white adipocytes. This suggests that brown adipocytes make use of alternative secretion pathways such as vesicular trafficking more frequently than white adipocytes. Further, we observed that mitochondrial creatine kinase U-type (CKMT1) was more abundant in the media from brown adipocytes. This protein is involved in BAT mitochondrial energy metabolism (Kazak et al., 2015) and has gained interest as a human BAT-selective protein (Müller et al., 2016).

Among the proteins that were secreted in higher amounts from the brown adipocytes in our MS data of the adipocyte media suggest that brown adipocytes might have higher anti-inflammatory capacity compared to white adipocytes. To verify our findings, we performed western blots on cell culture media from the brown and white adipocytes. In concordance, CFH immunoreactive protein was detected at relatively greater abundance in the media from brown adipocytes compared to white adipocytes (Figure 2K), and mRNA expression of CFH was higher in brown adipocytes versus white adipocytes (Figure 2L).

(C) FABP4 mRNA expression.
(D) UCP1 mRNA expression.
(E) UCP1 mRNA induction, calculated as fold change between unstimulated and norepinephrine (NE) stimulated adipocytes (4 h stimulation).
Data in (B)–(E) are mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001.
(F) Proteomics workflow.
(G) Overlap of the total amount of identified proteins between the different conditions, before and after filtering for proteins predicted to be secreted.
(H) Categorization of identified proteins before and after filtering for proteins predicted to be secreted.
(I) Overlap between identified secreted proteins and databases of secreted proteins; Vesiclepedia and ExoCarta.
See also Figure S1 and Table S1.
Figure 2. The Quantified Secretomes of Human Brown and White Adipocytes
(A) Representative Pearson correlation between two samples within the same group (brown adipocytes derived from two different individuals without NE stimulation).
A Distinct Secretome of Brown Adipocytes Identifies EPDR1 as a Candidate Batokine

Data-dependent quantitative proteomics data may contain a high percentage of missing values and systemic evaluation of the differentially expressed proteins is therefore important. For the comparative mapping described above, we imputed the missing values to best simulate the Gaussian distribution of low abundant proteins when comparing the secretomes of brown and white adipocytes, and we quantified more than 1,000 proteins expressed in cell media from both cell types, allowing for fold change comparison. However, we were concerned about the possibility that the imputation might mask differential regulation of low abundant proteins, even though the imputed values are downshifted. Thus, to avoid exclusion of any secreted protein that were selectively higher in the secretomes of either brown or white adipocytes, we investigated their selective secretomes separately. Using this approach, we exclusively quantified 101 proteins in the cell culture media from brown adipocytes, and 37 in the cell culture media from white adipocytes all these proteins were considered potentially secreted according to our criteria (Figure 3A; Table S2). Among the 101 proteins secreted from brown adipocytes was mammalian ependymin-related protein 1 (EPDR1) (Figure 3B). EPDR1 had previously been shortlisted in a TMT-labeling-based secretomics study of PR/SET domain 16 (PRDM16)-induced browning in mice (Svensson et al., 2016). We found EPDR1 to be exclusively quantified in BAT cell media (Figures S2A and S2B), while the imputation (Figure S2B) explains why EPDR1 was not annotated as differentially expressed in the volcano plot comparing the secretomes of white and brown adipocytes (Figure S2C). Consistent with these findings, EPDR1 mRNA levels were higher in brown adipocytes compared to white adipocytes (Figure 3C). The EPDR1 gene encodes three transcript variants, translated to three protein isoforms, of which two include an N-terminal signal peptide for secretion. We detected peptides unique to the secreted isoform 1, confirming its presence in our samples. Peptides mapping to isoform 2 (secreted) and isoform 3 (not secreted) were also detected, but these peptides also mapped to isoform 1; thus, their presence in our samples could be neither confirmed nor excluded (Figure 3D). These results do not exclude a low-level secretion of EPDR1 from white adipocytes. To further assess this, we performed a targeted proteomics of EPDR1. Notably, only one peptide could be quantified. Importantly, this peptide was unique to the secreted isoform 1, and the quantification confirmed that EPDR1 secretion is higher in cell media from brown adipocytes compared to media from white adipocytes (Figures S2D and S2E). We thus conclude that EPDR1 is selectively secreted from brown adipocytes yet also produced by white adipocytes, albeit likely in minimal amounts. Isoform 1 has been assigned as the canonical sequence, and as our data indicated that this isoform was detected in the brown adipocyte cell media, we decided to focus on this variant in our downstream experiments. As revealed by the crystal structure, EPDR1 has hydrophobic binding grooves and can interact with liposomes, suggesting a potential role in lipid transport (Wei et al., 2019).

To investigate the role of EPDR1 in brown adipocytes, we performed small interfering RNA (siRNA)-mediated knockdown. As the protein was expressed already at the onset of differentiation (Figure 3E), we transfected human brown adipocytes at day 0 of differentiation and measured EPDR1 mRNA levels after 24 h and again after the full 12-day differentiation program. The siRNA knockdown was highly efficient and had a sustained effect throughout differentiation (Figure 3E). EPDR1 mRNA levels were higher in the mature adipocytes than the early differentiation state (Figure 3E). The knockdown was also confirmed at the protein level (Figure S2F).

We observed no visual changes in lipid droplet accumulation or mitochondrial content following knockdown (Figure S2H). However, we found a decrease in the metabolic response to adrenergic signaling in brown adipocytes transfected with EPDR1 siRNA, as NE-induced proton leak was decreased (Figures 3F and 3G). In concordance, NE-induced upregulation of the thermogenic markers Dio2, Ucp1, Pparγc1a, Ppara, and Ckm1 was blunted in these cells (Figure 3H). We validated these data using two additional siRNA oligos, also targeting EPDR1, and could reproduce the effects on Ucp1 regulation (Figure S2G). To further assess the effects of EPDR1 knockdown, we measured a range of thermogenic and adipogenic markers. Whereas many thermogenic and adiopogenic markers remained unchanged following EPDR1 knockdown (Figures S2I and S2J), we found that the blunted thermogenic activation was accompanied by a reduced expression of Glut4, a key adipogenic marker (Figure 3I) and an increased expression of Col1a2 and Pdgfra, suggesting a potential increase in an undifferentiated, fibroblastic state (Sun et al., 2017) (Figure 3J). Interestingly, Cited1, a beige fat marker (Sharp et al., 2012), was also increased (Figure 3J).

To further understand the metabolic deficiency in the cells differentiating with reduced amounts of EPDR1, we performed

(B) PCA plot, including all proteins quantified in brown and white adipocytes with (NE) and without NE (wo NE) stimulation.
(C) Quantified proteins in the datasets with hormone activity, as annotated with the gene ontology molecular function (GOMF) term. NQ, not quantified.
(D) Quantified proteins in the datasets with growth factor activity, identified with GOMF term.
(E) PCA plot, including all quantified proteins in unstimulated brown and white adipocytes.
(F) Volcano plot depicting a two-sample t test between all quantified proteins in unstimulated brown and white adipocytes.
(G) Heatmap of all differentially regulated proteins between unstimulated brown and white adipocytes, as determined by two-sample t test.
(H) ECM proteins in white adipocytes compared to brown adipocytes.
(I) Secreted amounts of complement factor H (CFH). Values represent Z score from the mass spectrometry analysis of cell media.
Data in (B)(I) are based on n = 5 brown adipocytes and n = 5 white adipocytes, biological replicates, all from separate human donors.
(J) Mass spectrometry trace of CFH.
(K) Western blot of CFH in brown and white adipocyte culture media from brown adipocyte cultures (n = 3) and white adipocyte cultures (n = 3); biological replicates, all from separate human donors.
(L) CFH relative mRNA levels in white (n = 5) and brown (n = 5) adipocytes, all derived from separate human donors. Data are mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001.
See also Table S2.

6 Cell Metabolism 30, 1–13, November 5, 2019
Figure 3. Identification and In Vitro Characterization of EPDR1, a Novel Batokine Candidate
(A) Venn diagram illustrating quantified proteins annotated as secreted.
(B) Example of EDPR1 unique peptides sequenced by mass spectrometry.

Please cite this article in press as: Deshmukh et al., Proteomics-Based Comparative Mapping of the Secretomes of Human Brown and White Adipocytes Reveals EPDR1 as a Novel Batokine, Cell Metabolism (2019), https://doi.org/10.1016/j.cmet.2019.10.001

(legend continued on next page)
a cellular proteomics analysis on brown adipocytes derived from four human subjects and transfected at day 0 of differentiation with either siRNAs targeting EPDR1 or a non-targeting siRNA control. Cells were differentiated in vitro and harvested on day 12. We quantified 3,164 proteins in total of which 47 proteins were upregulated, and 53 proteins were downregulated following EPDR1 knockdown (Table S3). Among the downregulated proteins were EPDR1 and GLUT4, consistent with our mRNA data (Table S3). To relate the proteomics data to the deficiency in NE-induced proton leak, we investigated whether mitochondria-associated proteins were among the regulated proteins. Indeed, the list of regulated proteins included 23 mitochondrial proteins (UniProt GO and Keywords annotation) of which 6 proteins were upregulated, whereas 17 were downregulated (Figure 3K). Among the downregulated molecular entities were key mitochondrial proteins, such as NDUFA11 and NDUFS8, core subunits of complex I in the mitochondrial respiratory chain; COX6A1, the terminal oxidase in mitochondrial electron transport; and CKMT1A, a key protein in creatine kinase-dependent thermogenesis (Kazak et al., 2015). Taken together, these data indicate that adipocytes lacking EPDR1 during differentiation exhibit a hampered mitochondrial phenotype, reducing the functional capacity of the mature brown adipocyte.

To further address this, we examined the status of interscapular brown fat (iBAT) in a previously uncharacterized Epdr1−/− whole-body knockout mouse. Interestingly, we found that ex vivo oxygen consumption was reduced in iBAT from Epdr1−/− compared to wild-type mice at 20 weeks of age (Figure 3L). This deficiency in thermogenic function was accompanied by a reduction in Dio2 and Ppargc1a mRNA levels in the Epdr1−/− mice compared to wild-type mice, whereas Ucp1 and Ppargc1a mRNA levels remained unchanged (Figure 3M). Moreover, Epdr1−/− mice had a pronounced accumulation of body fat compared to control mice (Figure 3N), while total body weight was not different between groups (Figure 3O). These data, while encouraging, and directionally consistent with the totality of the mRNA data (Table S3). To relate the proteomics data to the deficiency in NE-induced proton leak, we investigated whether mitochondria-associated proteins were among the regulated proteins. Indeed, the list of regulated proteins included 23 mitochondrial proteins (UniProt GO and Keywords annotation) of which 6 proteins were upregulated, whereas 17 were downregulated (Figure 3K). Among the downregulated molecular entities were key mitochondrial proteins, such as NDUFA11 and NDUFS8, core subunits of complex I in the mitochondrial respiratory chain; COX6A1, the terminal oxidase in mitochondrial electron transport; and CKMT1A, a key protein in creatine kinase-dependent thermogenesis (Kazak et al., 2015). Taken together, these data indicate that adipocytes lacking EPDR1 during differentiation exhibit a hampered mitochondrial phenotype, reducing the functional capacity of the mature brown adipocyte.

To further address this, we examined the status of interscapular brown fat (iBAT) in a previously uncharacterized Epdr1−/− whole-body knockout mouse. Interestingly, we found that ex vivo oxygen consumption was reduced in iBAT from Epdr1−/− compared to wild-type mice at 20 weeks of age (Figure 3L). This deficiency in thermogenic function was accompanied by a reduction in Dio2 and Ppargc1a mRNA levels in the Epdr1−/− mice compared to wild-type mice, whereas Ucp1 and Ppargc1a mRNA levels remained unchanged (Figure 3M). Moreover, Epdr1−/− mice had a pronounced accumulation of body fat compared to control mice (Figure 3N), while total body weight was not different between groups (Figure 3O). These data, while encouraging, and directionally consistent with the totality of the EPDR1 data, should be interpreted with caution, as only a small number of mice were available for analysis and control mice were not littermates but were age- and gender-matched wild-type C57BL/6J.

Taken together, these data suggest that reduced levels of EPDR1 during differentiation results in incomplete brown fat commitment and thus propose a role for EPDR1 in thermogenic differentiation, perhaps as part of an auto- or paracrine circuit.

**EPDR1 Affects Metabolism Independently of BAT Activity**

Further characterization of the Epdr1 whole-body knockout mouse revealed that at 9–11 weeks of age, the Epdr1−/− mice had a lower oxygen consumption than wild-type mice, which was mostly pronounced in the dark phase (Figure 4A). Interestingly, this was accompanied by a decrease in physical activity (Figure 4B) without differences in food intake (Figure 4C). These data suggested that the metabolic effects of mice lacking Epdr1 in all tissues were not restricted to BAT.

To further investigate the effects of EPDR1 on whole-body metabolism, we produced recombiant EPDR1 (human isofrom 1) (Figure S3A) and injected 14-week-old C57BL/6NJ mice with EPDR1 protein at 2 mg/kg. Mice were acclimatized to thermoneutrality prior to the injection, allowing us to assess whether EPDR1 had any effect on metabolism independently of cold stimulation. The injection was given just prior to the dark period, when BAT activity is naturally increased by murine circadian rhythm (Gerhart-Hines et al., 2013). Hence, we studied the effect of EPDR1 without cold stimulation but when BAT was metabolically primed. We recorded whole-body metabolism throughout the dark period using indirect calorimetry. Subcutaneous injection of EPDR1 protein resulted in an increase in oxygen consumption during a 12-h period as compared with control mice injected with PBS (Figure 4D). A corresponding increase in energy expenditure was observed, while respiratory exchange ratio (RER) remained unchanged (Figure S3B). Whereas no difference in locomotor activity was detected (Figure 4E), the increase in oxygen consumption was followed by a subsequent increase in food intake (Figure 4F), exemplifying the fine-tuned synergy between energy expenditure and energy intake (Contreras et al., 2014, 2017; Sutton et al., 2014). Based on the reduced...
Figure 4. Effects of EPDR1 on Whole-Body Metabolism

(A) Oxygen consumption in Epdr1-/- (n = 4) or age-matched Epdr1+/+ controls (n = 6).
(B) Locomotor activity in Epdr1-/- (n = 4) or age-matched Epdr1+/+ controls (n = 6).

Please cite this article in press as: Deshmukh et al., Proteomics-Based Comparative Mapping of the Secretomes of Human Brown and White Adipocytes Reveals EPDR1 as a Novel Batokine, Cell Metabolism (2019), https://doi.org/10.1016/j.cmet.2019.10.001
physical activity observed in the Epdr1−/− mice, we performed a linear regression analysis of the EPDR1-induced increases in oxygen consumption and physical activity, respectively. This revealed a correlation ($R^2 = 0.28$, $p = 0.001$), and the EPDR1-induced increase in oxygen consumption could thus at least partly be explained by elevated physical activity (Figure 4G). Consistent with this finding, we found no induction of genes linked to thermogenic activation (Figure 4H). In fact, we found a modest downregulation of Ucp1, while the rest of the markers were unchanged (Figure 4H).

Acute BAT activation in humans can be quantified by performing a PET/CT scan using a radioactive glucose tracer (Chen et al., 2016). This method can also be applied in anesthetized mice (Sustarsic et al., 2018). Although our data did not support that the increase in oxygen consumption was due to increased BAT activity, we decided to investigate this further using [18F] FDG-PET/CT scanning. Moreover, we aimed to assess whether a potential activation was interacting with a sympathetic tone. Therefore, we performed an experiment where EPDR1 was injected into C57BL/6NRj mice simultaneously with either PBS vehicle or the β3-agonist CL-316,243 (CL). Uptake of a glucose tracer ([18F] FDG) was then assessed by PET/CT in anesthetized animals. We observed a substantial increase in FDG uptake in mice that were injected with CL, but no further activity was detected with EPDR1 injections (Figures 4I and 4J). Consistent with the gene expression data obtained from the mice in the metabolic chambers, we observed a down-regulation of Ucp1, and in this case, Prdm16 was also reduced whereas other thermogenic markers including Dio2, Ppargc1a, and Pparα remained unchanged (Figure S3C). In conclusion, EPDR1 affected metabolism but without enhancing BAT activity. Importantly, EPDR1 is expressed in other tissues, including the brain (Wei et al., 2019), possibly explaining the observed effects on metabolism.

To assess whether treatment with EPDR1 had any long-term effects on whole-body metabolism, we fed C57BL/6NRj mice a HFD and injected them with EPDR1 once daily for 21 days. We observed no difference in metabolic phenotype between the groups receiving EPDR1 compared to the group receiving PBS (Figure S3D). These mice were housed at room temperature, which is an appreciable cold stimulation and therefore could have masked EPDR1-dependent effects. Interestingly, we did observe an increase in Ucp1 expression in WAT of mice that had been injected with EPDR1 protein (Figure 4K). Consistent with the lack of whole-body metabolic effects, the upregulation of Ucp1 in the WAT following repeated injections of EPDR1 was very modest. This needs to be interpreted in the light of the mechanism of white fat browning. It has been reported that subpopulations of thermogenic adipocytes can be induced within epididymal (Petrovic et al., 2010) or inguinal (Seale et al., 2011) adipose tissues. It has further been demonstrated that thermogenic precursor cells co-exist with white fat precursor cells in the white fat depot (Wu et al., 2012). Therefore, measuring the whole tissue mRNA levels will likely dilute the upregulation of Ucp1 limited to a thermogenic subpopulation. The reason that Ucp1 expression in IBAT is not increased following the chronic stimulation is likely due to the room temperature housing conditions, which already result in efficient BAT recruitment (Sanchez-Gurmaches et al., 2018). Finally, we investigated whether EPDR1, as a secreted protein, could be detected in human plasma using a commercially available ELISA kit with a detection level of 30 ng/mL. We found that circulating EPDR1 was detected in seven out of thirty adult humans (Table S4). Interestingly, the subjects that were positive for EPDR1 had higher levels of UCP1 mRNA in their deep neck brown adipose tissue, consistent with the possibility that EPDR1 could be secreted into the circulation perhaps from metabolically active BAT in humans (Figure 4L).

Collectively, we here provide the first comprehensive analysis of the human brown adipocyte secretome compared to the white adipocyte secretome in a basal state and following an acute NE stimulation. Our results reinforce that brown and white adipocytes have distinct secretory profiles and metabolic functions. We identify a large number of novel candidate batokines. Among several interesting candidates, we focused on the role of a novel human batokine, EPDR1, which is selectively secreted from brown adipocytes. We demonstrate that EPDR1 is vital for development into a functional thermogenic adipocyte, and our data further indicate that EPDR1 can act in an endocrine fashion. In conclusion, our data illuminate the human BAT secretome and provides a promising source of novel metabolic regulators that could serve as an important resource for future studies, including evaluation of potential drug targets for mediating improved metabolic control.
Limitations of Study
Regarding the secretome analysis, methodological limitations could have resulted in that low abundant secreted proteins were not detected. Moreover, as we could exclude that some of the identified proteins originated from fragmented cells, we designed a computational pipeline to filter out proteins that were not likely to be secreted. This might, however, have resulted in removal of proteins that were secreted. On the other hand, we might have included proteins that were fragmentation products. Nevertheless, if any cell fragmentation had occurred, it is reasonable to expect that it occurred to the same extent between white and brown adipocytes as culturing and incubation conditions were identical. Our secretome analysis is done in mature adipocytes, but levels of (brown) adipokines differ during differentiation (Zhong et al., 2010). Analyses of more time points in the differentiation process could provide additional future insights into the secretory differences between white and brown adipocytes. We identify EPDR1 as a novel batokine, important for brown fat determination, whereas the exact pathway through which EPDR1 acts remains to be explored.

STAR METHODS
Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **LEAD CONTACT AND MATERIALS AVAILABILITY**
  - Disclosure of Limited Availability of Biological Material
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Human Supraclavicular (Brown) and Subcutaneous (White) Fat Precursor Cells
  - Human Subjects
  - Mouse Models
- **METHOD DETAILS**
  - Human Primary Adipocyte Culture Conditions
  - siRNA Mediated Knockdown of EPDR1 in Adipocytes
  - RNA Isolation and Quantitative Real-Time PCR of Adipocytes
  - Oxygen Consumption Measurements in Adipocytes
  - Lipid and Mitochondrial Staining
  - ELISA
  - EPDR1 Production
  - Assessment of the Purity of EPDR1 Recombinant Protein
  - Small Animal [18F] FDG PET/CT Imaging
  - RNA Isolation and Quantitative Real-Time PCR following EPDR1 Injection
  - Indirect Calorimetry following EPDR1 Injection
  - Body Composition, Food Intake and Indirect Calorimetry in EPDR1+/- Mice
  - Ex Vivo Oxygen Consumption
  - RNA Isolation and Quantitative Real-Time PCR in EPDR1+/- Mice
  - Secretome Analysis by Mass Spectrometry
  - Sample Preparation for Secretome and Cellular Proteome
  - LC MS/MS Analysis
  - Computational MS Data Analysis

- Predictive Multiplexed Selective Ion Monitoring (pmSIM)
- Western Blot Analysis on Cell Media
- Western Blot Analysis on Cell Lysate
- QUANTIFICATION AND STATISTICAL ANALYSIS
- DATA AND CODE AVAILABILITY

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.cmet.2019.10.001.

ACKNOWLEDGMENTS
We thank Jacob Steen Petersen and Birgitte Andersen from Novo Nordisk A/S for valuable scientific discussion, and Kirsten L. Meeke and Charlotte Wittrup from Minerva Imaging ApS for help with the scanning and data analysis. The Centre for Physical Activity Research (CFAS) is supported by TrygFonden (grant IDs 101390 and ID 20049). During the study period, the Center of Inflammation and Metabolism (CIM), Rigshospitalet, was supported by a grant from the Danish National Research Foundation (DNRF50). CIM/CFAS is a member of DD2, the Danish Center for Strategic Research in Type 2 Diabetes (the Danish Council for Strategic Research, grant nos. 09-067009 and 09-075724). Novo Nordisk Foundation Center for Basic Metabolic Research is an independent Research Center, based at the University of Copenhagen, Denmark, and partially funded by an unconditional donation from the Novo Nordisk Foundation (https://cbmf.ku.dk/) (grant no. NNF18CC0034900). Novo Nordisk Foundation Center for Protein Research (NNF14CC001) (https://www.cpr.ku.dk/) is supported by an unconditional grant from the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Programme (grant agreement no. 639382). N.Z.J. is supported by a research grant from the Danish Diabetes Academy, which is funded by the Novo Nordisk Foundation (grant no. NNF17SA0031406). P.G. and R.B.-O. were supported by the Danish Research Foundation of Independent Research (grant no. DFF-6110-00489). The study was further funded by a shared research grant from Novo Nordisk A/S to C.S. and M.M. and by a grant to C.S. from the Novo Nordisk Foundation (grant no. NNF18CC0034378).

AUTHOR CONTRIBUTIONS

DECLARATION OF INTERESTS
D.J.D. has served as an advisor or consultant or speaker within the past 12 months to Forkhead Biotherapeutics, Helioine Inc., Intarcia Therapeutics, KalyoPre, Merck Research Laboratories, Novo Nordisk Inc., Pfizer Inc., and Sanofi Inc. C.H., M.T.C., and A.S. are employees and shareholders at Novo Nordisk A/S. Z.G.H. works, in some capacity, for Embark Biotech Aps developing therapeutics for the treatment of diabetes and obesity.

Received: September 18, 2018
Revised: April 26, 2019
Accepted: October 2, 2019
Published: October 24, 2019

Cell Metabolism 30, 1–13, November 5, 2019 11
REFERENCES


### STAR METHODS

#### KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rabbit Polyclonal anti-UCC1 (EPDR1), 1:1000</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#PA5-50404; RRID: AB_2635857</td>
</tr>
<tr>
<td>Mouse Monoclonal anti-α-Tubulin (clone DM1A), 1:1000</td>
<td>Sigma-Aldrich (Merck)</td>
<td>Cat#T9026; RRID: AB_477593</td>
</tr>
<tr>
<td>Mouse polyclonal anti-CFH, 1.8 μg/ml</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Biological Samples</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human supraclavicular brown adipocytes and subcutaneous white adipocytes</td>
<td>Jespersen et al., 2013</td>
<td>N/A</td>
</tr>
<tr>
<td>Human supraclavicular brown adipose tissue</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Human plasma samples</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Chemicals, Peptides, and Recombinant Proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seahorse XF base medium</td>
<td>Agilent</td>
<td>Cat#103335-100</td>
</tr>
<tr>
<td>FGF-1</td>
<td>Immunotools</td>
<td>Cat#11343557</td>
</tr>
<tr>
<td>Transferrin</td>
<td>Sigma-Aldrich (Merck)</td>
<td>Cat#T8158</td>
</tr>
<tr>
<td>T3</td>
<td>Sigma-Aldrich (Merck)</td>
<td>Cat#T5516</td>
</tr>
<tr>
<td>Rosiglitazone</td>
<td>Sigma-Aldrich (Merck)</td>
<td>Cat#R2408</td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>Sigma-Aldrich (Merck)</td>
<td>Cat#D4902</td>
</tr>
<tr>
<td>IBMX</td>
<td>Sigma-Aldrich (Merck)</td>
<td>Cat#I5879</td>
</tr>
<tr>
<td>DMEM/F-12, HEPES, no phenol red</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#11039-047</td>
</tr>
<tr>
<td>FBS</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#10270106</td>
</tr>
<tr>
<td>Opti-MEM I Reduced Serum Medium</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#31985062</td>
</tr>
<tr>
<td>Lipofectamine RNAiMAX Transfection Reagent</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#13778150</td>
</tr>
<tr>
<td>Sodium pyruvate</td>
<td>Sigma-Aldrich (Merck)</td>
<td>Cat#5280</td>
</tr>
<tr>
<td>L-Glutamine</td>
<td>Sigma-Aldrich (Merck)</td>
<td>Cat#G5126</td>
</tr>
<tr>
<td>D(-) Glucose</td>
<td>Sigma-Aldrich (Merck)</td>
<td>Cat#G7021</td>
</tr>
<tr>
<td>MitoTracker Red CMXRos</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#M7512</td>
</tr>
<tr>
<td>NucBlue Fixed Cell ReadyProbes Reagent</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#R37606</td>
</tr>
<tr>
<td>PBS, pH 7.4</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#10010049</td>
</tr>
<tr>
<td>PowerUp SYBR Green Master Mix</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#A25777</td>
</tr>
<tr>
<td>TaqMan Universal PCR Master Mix</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#4305719</td>
</tr>
<tr>
<td>BODIPY 493/503</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#D-3922</td>
</tr>
<tr>
<td>NORadrenalin SAD</td>
<td>Amgros I/S</td>
<td>Cat#745661</td>
</tr>
<tr>
<td>Insulin (Actrapid)</td>
<td>Novo Nordisk</td>
<td>Cat#A10AB01</td>
</tr>
<tr>
<td>EPDR1 protein</td>
<td>Novo Nordisk</td>
<td>N/A</td>
</tr>
<tr>
<td>High fat diet for rodents with lard (60% kJ fat)</td>
<td>Sniff</td>
<td>D12495</td>
</tr>
<tr>
<td><strong>Critical Commercial Assays</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High-Capacity cDNA Reverse Transcription kit</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#4374966</td>
</tr>
<tr>
<td>Direct-zol RNA miniprep kit</td>
<td>Zymo Research</td>
<td>Cat#R2063</td>
</tr>
<tr>
<td>Seahorse XFe96 FluxPak</td>
<td>Agilent</td>
<td>Cat#102416-100</td>
</tr>
<tr>
<td>EPDR1 ELISA kit</td>
<td>MyBioSource</td>
<td>Cat#M8S9316185</td>
</tr>
<tr>
<td>Seahorse XF Cell Mito Stress Test Kit</td>
<td>Agilent</td>
<td>Cat#103015-100</td>
</tr>
<tr>
<td>Bio-Rad Protein Assay</td>
<td>Bio-Rad</td>
<td>Cat#5000006</td>
</tr>
<tr>
<td><strong>Deposited Data</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raw and processed MS data</td>
<td>ProteomeXchange Consortium</td>
<td>PXD008541</td>
</tr>
</tbody>
</table>

(Continued on next page)
LEAD CONTACT AND MATERIALS AVAILABILITY

Requests for reagents and resources should be directed to the Lead Contact, Camilla Scheele (cs@sund.ku.dk).

Disclosure of Limited Availability of Biological Material
We hereby disclose that the availability of biological material including the human cell cultures and tissue, is dependent on specific permission from the Danish Data Protection Agency and on the researcher’s adherence to the specifications of this permission.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Human Supraclavicular (Brown) and Subcutaneous (White) Fat Precursor Cells
Brown fat precursor cells were isolated from the supraclavicular adipose depot of a cohort of adult humans (n = 21), as previously reported along with a subset of the cell cultures (Jespersen et al., 2013). These non-immortalized cell cultures were differentiated in vitro and the five cultures (from different individuals) displaying the best differentiation capacity in terms of lipid accumulation and the highest induction of UCP1 expression in response to norepinephrine (NE) were included in the study (Figure S1). The five brown fat precursor cultures were derived from two women and three men. White fat precursor cells were obtained from the subcutaneous abdominal region of three women and two men, with equal distribution of age and body mass index (BMI) as the donors of the brown fat cell cultures. All subjects provided written informed consent. The Scientific-Ethics Committees of the Capital Region and Copenhagen and Frederiksberg Municipalities Denmark approved the study protocols, journal numbers H-A-2009-020, H-A-2008-081, and (KF) 01-141/04, respectively, and the studies were performed in accordance with the Helsinki declaration.

Human Subjects
The human tissue and plasma samples used for this study are a subset from a cohort of subjects undergoing surgery for benign goiter. All subjects provided written informed consent prior to participation. The Scientific-Ethics Committees of the Capital Region of Denmark approved the study protocol and amendments, and the study was performed in accordance with the Helsinki declaration journal number H-1-2014-015. A subset of 30 non-obese normal glucose tolerant subjects were included in the current study. Surgical biopsies were obtained from the deep neck region and were snap-frozen in liquid nitrogen until RNA isolation was performed. Subject characteristics of EPDR1 positive and EPDR1 negative subjects are presented in Table S4.

Mouse Models

EPDR1 Injections
Animal studies were approved by the Animal Experimentation Inspectorate of the Danish Ministry of Justice no 2014-15-0201-00181. Mice were raised under Specific Pathogen Free (SPF) conditions. Acute injections: The animals were single housed and maintained at a 12-h light-dark cycle in temperature (30°C–32°C) and humidity (50–60%) controlled cabinets, with free access to standard chow (Altromin 1314F, pellets) and tap water. Chronic injections: The animals were maintained at a 12-h light-dark cycle in temperature (20°C–22°C) and humidity (50–60%) controlled cabinets, with free access to tap water and high fat diet (60 kJ%) fat) from 6 weeks of age. At 22 weeks of age, the animals were single housed and placed in calorimetric chambers. Estimation of sample sizes were based on previous studies with similar metabolic readouts (Sustarsic et al., 2018).
Epdr1 Knockout Mouse Model

Animal studies were approved by the Toronto Centre for Phenogenomics Mt. Sinai Hospital, in Toronto. Mice were raised under SPF conditions. The mouse line C57BL/6N-Epdr1<tm1a(NCOR)Mfgc>/Tcp was generated at the Toronto Centre for Phenogenomics (TCP) and obtained from the Canadian Mouse Mutant. Repository as part of the NorCOMM2 project from NorCOMM ES cells (Bradley et al., 2012). Male mice generated from this mouseline were fed a regular standard rodent chow (18% kcal from fat, 2018 Harlan Teklad, Mississauga, ON) for 20 weeks. Epdr1-/- mice were gender and age matched to wild-type mice generated at the TCP facility that were not littermate controls.

METHOD DETAILS

Human Primary Adipocyte Culture Conditions

The protocols for isolation and differentiation of human fat precursor cells has been thoroughly described and discussed (Larsen et al., 2019). Cells were plated and maintained in DMEM F12 (Thermo Fisher Scientific) containing 10% FBS, 1% Penicillin/Streptomycin and 1nM FGF1 (Immunotools). Two days post confluence (designated day 0) the cells were induced to differentiate by replacing the medium with 10 mM 3-Isobuty-1-methylxanthine (IBMX). At day 3, the medium was replaced with the same medium composition, with the exemption of IBMX. The cells were refed with new medium at day 6 and day 9 with the exemption of Rosiglitazone. At day 12, cells were considered fully differentiated mature adipocytes. Secretome analysis was performed on supravacuolar (n=5) and subvacuol- ous (n=5) cells. For secretion analysis, fully differentiated cells were washed with DMEM/F12 and subsequently incubated for 2 h in DMEM/F12 containing 1% penicillin-streptomycin. Serum-starved cells were stimulated with 10 µM norepinephrine (NE) (Sigma-Aldrich) for 4 h. Cell culture media (2 ml) was collected for secretome analysis while cells were harvested for RNA analysis. To address whether cell viability was affected by NE treatment, cells were stained according to the manufacturer’s protocol, applying a LIVE/DEAD fluorescent assay (Thermo Scientific) visualized using an EVOS FL fluorescent microscope (Thermo Scientific).

siRNA Mediated Knockdown of EPDR1 in Adipocytes

At day 0 of the differentiation program, adipocytes were transfected with 22.2 nM siRNA targeting EPDR1 or a non-targeting pool (Dharmacon) (Table S5) using Lipofectamine RNAiMAX Reagent (Thermo Fisher Scientific) according to the manufacturer’s instructions. The cells were then cultured as described in the previous section. To investigate whether our siRNA mediated knockdown of EPDR1 (using a pool targeting four different sites on the EPDR1 mRNA transcript and a non-targeting siRNA control) targeted the secreted isoforms of EPDR1 (transcript variant 1 and transcript variant 2), we designed qPCR primers specifically targeting either of these transcripts. A unique qPCR assay for the intracellular transcript variant 3 could not be designed, but a qPCR assay for assessment mRNA of all three transcript variants of EPDR1 was designed (Figures S4A–S4C; Table S5). To ensure that the knockdown was specific for EPDR1 we also measured mRNA expression of SFRP4, which is located in the same locus as EPDR1, but transcribed from the opposite strand (Figure S4D). We validated the effects of EPDR1 knockdown on NE-induced thermogenic gene expression by transfecting with two additional siRNAs (Dharmacon) (Table S3), each targeting only one site of the mRNA molecule (Figure S2G). Finally, to investigate whether the observed reduction in induction of thermogenic gene expression following NE- stimulation in brown adipocytes following knockdown of EPDR1 was specific for brown adipocytes, we also measured thermogenic gene expression in human white adipocytes (Figures S4E–S4G).

RNA Isolation and Quantitative Real-Time PCR of Adipocytes

Total RNA from human adipocytes was isolated with TRIzol (Thermo Fisher Scientific), according to the manufacturer’s recommendations. RNA concentrations were measured using Nanodrop 1000, and 250 ng of RNA was used as input for subsequent cDNA synthesis with High Capacity cDNA Synthesis Kit (Thermo Fisher Scientific). Primer sequences can be found in Table S5. Target mRNA was normalized to PPIA and calculated using the comparative delta-delta-Ct method.

Oxygen Consumption Measurements in Adipocytes

Mitochondrial respiration rates were assessed using the XFe96 Extracellular Flux Analyzer (Agilent Technologies). Cells were plated at confluence (7000 cells/well) and transfected and differentiated as described above. The cell medium was replaced with Seahorse Medium without phenol red, supplemented with 1 µM L-Glutamine, 2 µM Na2PO4 and 25 mM Glucose pH 7.4 1 h prior to respiration measurements. Oxygen consumptions rates were followed under basal conditions, NE (1 µM) injection and finally oligomycin injection (20 µM).

Lipid and Mitochondrial Staining

Mature adipocytes were incubated with DMEM/F12 containing 0.2µM MitoTracker Red CMXRos (Thermo Fisher Scientific) for 20 min. Cells were then washed 3 times with PBS and fixed with 4% formaldehyde (Sigma-Aldrich) for 15 min. Fixed cells were washed again 3 times with PBS, and lipid were stained with 0.5 mM Bodipy (Thermo Fisher Scientific) for 20 min. Subsequently nuclei were stained with NucBlue Fixed Ready Probe Reagent (Thermo Fisher Scientific) for 7 min. Cells were washed 3 times with PBS and visualized with EVOS FL imaging system (Thermo Fisher Scientific).
ELISA
EPDR1 Plasma concentrations were determined using a commercially available ELISA kit from Mybiosource. Briefly, 50 μl plasma were loaded in duplicates and EPDR1 abundance was determined. The detection limit of the kit was 30 ng/ml. UCP1 mRNA levels were determined using qPCR. Subject characteristics of EPDR1 positive and EPDR1 negative subjects are presented in Table S4.

EPDR1 Production
Production of recombinant human EPDR1 (UNIPROT entry Q9UM22, isoform 1, amino acids 39-224) was performed by transfecting expi293F cells growing in suspension culture in Expi293 Expression medium (ThermoFisher Scientific, cat# A1435101) with a mix of ExpiFectamine 293 Reagent (ExpiFectamine 293 Transfection Kit, ThermoFisher Scientific, cat# A14525) and plasmid DNA encoding the relevant sequence. Transfection Enhancers 1 and 2 from the ExpiFectamine 293 Transfection Kit were added the day after transfection. The cell culture was harvested 4 days after transfection. The recombinant EPDR1 secreted into the culture medium contained a short N-terminal sequence consistent with affinity purification and the protein was purified by affinity chromatography followed by size exclusion chromatography according to standard chromatographic methods. The purified protein solution was sterilized by filtration through a 0.2 mm filter unit.

Assessment of the Purity of EPDR1 Recombinant Protein
The purity of the protein was analyzed by SDS-PAGE. Briefly, Histidine tagged EPDR1 was loaded (6 μg) on SDS PAGE either directly or after three freeze thawing cycles (3 μg). The gel was stained with Coomassie blue stain (Figure S3A). A silver staining was also performed. Briefly, 2.92 ng and 3.18 ng protein from batch 2 and batch 3 was loaded on 4-12% Bis-Tris Nu PAGE gels (Thermo Fischer Scientific). Silver staining was done using SilverXpress, Silver staining kit (Thermo Fisher Scientific) and performed as recommended by the manufacturer (Figure S3A). The protein purity was also checked by using size exclusion chromatography (SEC) and protein identity was confirmed by LC MS-MS (Figure S3A). The protein solution was analyzed for endotoxin levels: batch 1: 0.059 EU/mg (used for indirect calorimetry study) and batch 2: 0.055 EU/mg (used for daily injections of EPDR1 over 21 days) batch 3: 0.68 EU/mg (used for [18F] FDG PET/CT imaging). All batches were confirmed to be suitable for animal studies. To further ensure that the observed increases in oxygen consumption following acute EPDR1 injection in C57BL/6NRj mice housed at thermoneutrality, was specific for EPDR1 and were not associated to artifacts coming from protein preparation, we measured metabolic parameters following injection of two other proteins. The two proteins (GM2A and SBSN) were also specifically quantified in the culture media from brown adipocytes and proteins were prepared/purified in the same manner as EPDR1. All further experimental conditions were also identical between setups (Figures S4H–S4K).

Small Animal [18F] FDG PET/CT Imaging
Eight-week-old female mice were group housed at thermo neutrality on a 12:12 hour light/dark cycle (lights on at 9 PM and off at 9 AM). [18F] FDG was administrated intravenously between 10 AM and 2 PM. The average radioactive dose was 4.8 MBq (range: 3.6–5.8 MBq). EPDR1 (2 mg/kg) or PBS was administered subcutaneously 180 minutes prior to FDG injection, and CL 316,243 (1 mg/kg) or PBS was administered subcutaneously 15 min prior to FDG administration. Animals were fasted and housed in the dark at 29°C following injection of EPDR1.

Small animal PET/CT (Inveon Multimodality PET/CT scanner; Siemens) was performed 1 hour after FDG administration. Mice were anaesthetized by sevoflurane 40 minutes after FDG injection until the end of the imaging session. Heating was applied in order to maintain normal body temperature. PET data were acquired in list mode for 240s, and images were reconstructed using a 3-dimensional maximum a posteriori algorithm with CT-based attenuation and scatter correction. CT images were acquired using 360 projections, 65 kV, 500 mA, and 430 ms exposure and reconstructed with an isotropic voxel size of 0.210 mm. Images were analyzed using the Inveon software (Siemens). Quantitative analysis of the [18F]FDG uptake was performed by manually drawing region of interestes over the areas containing iBAT based on the CT images. The FDG uptake was expressed as % injected dose per gram tissue (%ID/g). Animals were euthanized after the imaging session and iBAT, iWAT, Soleus muscle and heart were excised, weighted, submerged in RNAlater for subsequent RNA isolation and gene expression analysis.

RNA Isolation and Quantitative Real-Time PCR following EPDR1 Injection
Total RNA was extracted from iBAT and WAT depots that was stored in RNAlater. The tissues were processed in Tri Reagent (Qiagen) using a TissueLyser II system (Qiagen) and RNasey Lipid Tissue Mini Kit according to instructions from the manufacturer. RNA concentrations were measured using Nanodrop 2000, and 500 ng of RNA was used as input for subsequent cDNA synthesis with High Capacity cDNA Synthesis Kit (Thermo Fisher Scientific). Primer sequences can be found in Table S5. Target mRNA was normalized to peptidylprolyl isomerase A (PPIA) and results were calculated using the comparative delta-delta-Ct method.
the dark cycle. Metabolic measurements were followed for a total of 43 hours, and the initial 12-hour dark period was used to assess treatment effects. For the chronic injection study, EPDR1 (2 mg/kg in PBS) or PBS as vehicle was administered subcutaneously in the middle of the light cycle. Metabolic measurements were followed for a total of 21 days and used to assess treatment effects.

**Body Composition, Food Intake and Indirect Calorimetry in EPDR1−/− Mice**

Body composition was measured using Echo nuclear magnetic resonance system (Echo Medical Systems, Houston, TX) MRI, in the non-fasted state around 10 am at 20 weeks of age. Food intake was averaged over a 3-day period where mice were housed individually. To measure oxygen consumption (ml/hr), carbon dioxide production, respiratory exchange ratio, activity, and energy expenditure (kcal/hr) the Comprehensive Lab Animal Monitoring System (CLAMS; Columbus Instruments, Columbus OH) was used when mice were 9-11 weeks of age.

**Ex Vivo Oxygen Consumption**
iBAT was immediately harvested from non-fasted animals after CO2 euthanasia. iBAT was split into 3 depots of similar size (~10 mg of scaled weight) and kept at DMEM high-glucose media at 37°C. Tissues were then washed in filtered respiration buffer (PBS, 0.02% fatty acid free BSA, 25-mM glucose, 0.01% (vol/vol) of 100 mM Na pyruvate (Sigma)), minced with scissors, re-suspended in 1-ml respiration buffer and placed into a Micorcell chamber (MT200A, Strathkelvin Instruments, North Lanarkshire, Scotland) also kept at 37°C with a Clark electrode (Strathkelvin). Recordings were normalized to tissue scaled weight and each data point represents an average oxygen consumption from 3 depots from each animal.

**RNA Isolation and Quantitative Real-Time PCR in EPDR1−/− Mice**

Total RNA was extracted from iBAT that was harvested immediately from mice after CO2 euthanasia in the non-fasted state and stored at -80°C until processed in Tri Reagent (Molecular Research Center, Cincinnati, ON) using a TissueLyser II system (Qiagen, Germantown, MD). First strand cDNA was synthesized from DNase I-treated total RNA using the SuperScript III and random hexamers (Thermo Fisher Scientific, Markham, ON). Gene expression levels were quantified by real-time PCR using a QuantStudio System and TaqMan Gene Expression Master Mix and Assays (Thermo Fisher Scientific). Primer/probes were purchased from Thermo Fisher Scientific (Table S5). qPCR data were analyzed by 2-DeltaDeltaCt method, and expression levels for each gene were normalized to Tbp (TATA-box-binding protein).

**Secretome Analysis by Mass Spectrometry**

A high-resolution mass spectrometry (MS)-based approach was used to detect a highly complex secreted protein mixture from human primary brown and white adipose cell cultures. Serum free cell supernatants were trypsin digested, and the resulting peptide mixtures were directly analyzed in a single-run LC-MS format. We performed liquid chromatography with 2 h gradient and analyzed peptides on bench top quadrupole-Orbitrap instrument with very high sequencing speed and high mass accuracy in MS and MS/MS modes (Michalski et al., 2011). Label-free quantification of the MS data is performed in the MaxQuant environment while bioinformatics analysis was done with Perseus software (Tyanova et al., 2016).

**Sample Preparation for Secretome and Cellular Proteome**

Secretome analysis of the conditioned media from brown and white adipocytes was performed as described before (Deshmukh et al., 2015) with slight modifications. Proteins in conditioned media were denatured with 2 M urea in 10 mM HEPES pH 10 by ultrasonication on ice and acetone precipitated (overnight). Protein pellets were washed with 80% acetone and suspended in urea (6 M) and thiourea (2 M) buffer (pH 8). Proteins were reduced with 10 mM dithiothreitol for 40 min followed by alkylation with 55 mM iodoacetamide for 40 min in the dark. Proteins were digested with 0.5 μg LysC (Wako) for 3 h and digested with 0.5 μg trypsin for 16 h at room temperature. The digestion was stopped with 0.5% trifluoroacetic acid, 2% acetonitrile. Peptides were desalted on reversed phase C18 StageTips. The peptides were eluted using 20 μl of 60% acetonitrile in 0.5% acetic acid and concentrated in a SpeedVac. Concentrated peptides were acidified with 2% acetonitrile, 0.1% trifluoroacetic acid in 0.1% formic acid. Samples for cellular proteome of BAT and WAT cells were prepared according to iST protocol (Kulak et al., 2014).

**LC MS/MS Analysis**

The peptides from the cell culture media were analyzed using LC-MS instrumentation consisting of an Easy nanoflow UHPLC (Thermo Fischer Scientific) coupled via a nanoelectrospray ion source (Thermo Fischer Scientific) to a Q Exactive mass spectrometer (Thermo Fischer Scientific) (Michalski et al., 2011). Peptides were separated on a 50-cm column with 75-μm inner diameter packed in-house with ReproSil-Pur C18-aq 1.9 μm resin (Dr. Maisch). Peptides were loaded in buffer containing 0.5% formic acid and eluted with a 160 min linear gradient with buffer containing 80% acetonitrile and 0.5% formic acid (v/v) at 250 nL/min. Chromatography and column oven (Sonation GmbH) temperature were controlled and monitored in real time using SprayQC (Schelterma and Mann, 2012). Mass spectra were acquired using a data dependent Top8 method, with the automatic switch between MS and MS/MS. Mass spectra were acquired in the Orbitrap analyzer with a mass range of 300-1650 m/z and 70 000 resolution at m/z 200. HCD peptide fragments were acquired with a normalized collision energy of 25. The maximum ion injection times for the survey scan and the MS/MS scans were 20 and 220 ms, and the ion target values were set to 3e6 and 1e5, respectively. Data were acquired using Xcalibur software. Peptides from BAT and WAT cells were analyzed using LC-MS instrumentation consisting of an Easy nanoflow UHPLC.
coupled via a nanoelectrospray ion source to a latest generation Q Exactive mass spectrometer (HFX) (Kelstrup et al., 2018). Peptides were separated on a 50 cm column with 75 μm inner diameter packed in-house with ReproSil-Pur C18-aq 1.9 μm resin (Dr. Maisch). Peptides were loaded in buffer containing 0.5% formic acid and eluted with a 100 min linear gradient with buffer containing 80% acetonitrile and 0.5% formic acid (v/v) at 350 nL/min. Mass spectra were acquired using a data-dependent Top15 method, with the automatic switch between MS and MS/MS. Mass spectra were acquired in the Orbitrap analyzer with a mass range of 300-1650 m/z and 60 000 resolution at m/z 200. HCD peptide fragments were acquired with a normalized collision energy of 27. The maximum ion injection times for the survey scan and the MS/MS scans were 20 and 25 ms, and the ion target values were set to 3e6 and 1e5, respectively.

Computational MS Data Analysis

The raw files for secretome and cellular proteome were analyzed in the MaxQuant environment (Tyanova et al., 2016). The initial maximum allowed mass deviation was set to 6 ppm for monoisotopic precursor ions and 20 ppm for MS/MS peaks. Enzyme specificity was set to trypsin, defined as C-terminal to arginine and lysine excluding proline, and a maximum of two missed cleavages was allowed. A minimal peptide length of six amino acids was required. Carbamidomethylcysteine was set as a fixed modification, while N-terminal acetylation and methionine oxidation were set as variable modification. The spectra were searched by the Andromeda search engine against the human UniProt sequence database with 248 common contaminants and concatenated with the reversed versions of all sequences. The false discovery rate (FDR) was set to 1% for peptide and protein identifications. The peptide identifications across different LC-MS runs were matched by enabling the ‘match between runs’ feature in MaxQuant with a retention time window of 30 s. If the identified peptides were shared between two or more proteins, these were combined and reported in protein group. Contaminants and reverse identifications were removed from further data analysis. Protein quantification was based on the Max LFQ algorithm integrated into the MaxQuant software (Cox et al., 2014).

Bioinformatics analysis was performed with the Perseus software (Tyanova et al., 2016) (http://www.perseus-framework.org). Categorical annotation was supplied in the form of KEGG pathways, Keywords (UniProt), and Gene Ontology (GO) (biological process (BP), molecular function (MF), and cellular component (CC)). All annotations were extracted from the UniProt database. To define the secretome of brown and white adipocytes, we applied previously described computational workflow on all proteins identified in the media (Deshmukh et al., 2015). Briefly, signal peptide-containing proteins were categorized as ‘classical’ secreted proteins while protein annotated to ‘extracellular location’ (GOCC) or ‘secreted’ (UniProt, Keywords) were classified as ‘non-classical’ secreted proteins. While comparing proteins identified in the cell media from brown or white adipocytes with Vesiclepedia (Kalra et al., 2012) and ExoCarta databases (Keerthikumar et al., 2016), we included only evidence at the protein level.

The global comparative analysis was performed on LFQ intensities. We used very stringent criteria for MaxLFQ-based quantification (min ratio count 2 in MaxQuant). Moreover, we included only those proteins which were quantified at least 2 times in at least one group (i.e. Brown_woNE vs White_woNE) Due to the randomness of peptide sampling in shotgun proteomics, the quantification of several proteins is missing for some samples. The data was imputed to fill missing abundance values by drawing random numbers from a Gaussian distribution. These parameters have been tuned in order to simulate the distribution of low abundant proteins best. To investigate differences between brown and white adipocyte secretomes, we compared brown and white adipocyte proteome under non-stimulated (woNE) conditions while the effect of NE-stimulation was investigated by comparing stimulated and non-stimulated conditions (Brown_woNE vs Brown_NE/ White_woNE vs White_NE). These comparisons were made using a two-sample t-test in Perseus with FDR 0.05. Proteins which were regulated by 1.5-fold (Log2) were considered as significantly different quantitation of the samples. Hierarchical clustering of significantly different proteins was performed after Z-score normalization. We then performed Fisher exact test on significantly different proteins (background total quantified proteins), testing for enrichment or depletion of any annotation term in the cluster compared to the whole matrix.

Downstream analysis of global cellular proteome was performed in Perseus software. The statistical comparisons were made using a two-sample t-test in Perseus with FDR 0.05. Protein abundances were compared siCt vs siEPDR1 in human brown adipocytes. While comparing siCt vs siEPDR1 in human brown adipocytes, proteins with >1.2 log2 FC were considered as significantly differentially regulated.

Predictive Multiplexed Selective Ion Monitoring (pmSIM)

Predictive multiplexed selected ion monitoring (pmSIM) targeting in MaxQuantLive (version 1.0) for peptide and protein quantification relies on the real-time recalibration of retention time and mass accuracy based on background peptides and the identification of the heavy labeled counterpart of the to be quantified endogenous peptide of interest. Therefore, the heavy labeled EPDR1 peptide SYET-WIgYTVK was equally spiked into ready to inject brown and white fat secretomes and analyzed by data dependent acquisition on an orbitrap QE-HFX platform followed by MaxQuant (1.6.7) to identify retention time, intensity, and m/z of background peptides and the EPDR1 peptide SYET-WIgYTVK for pmSIM targeting of the endogenous counterpart. A total of 2743 shared realtime correction peptides were selected from the ‘evidence’ output file, removing potential contaminants, reverse database hits, modified sequences, miss cleaved peptides and peptides eluting in a time frame of <10 and >90min. For realtime correction, the initial retention time tolerance was ± 20 min and the final retention scale factor was set to three times the standard deviation of the recorded elution time with a mass tolerance of ± 9 ppm, and an intensity threshold of 10^6. MaxQuant.Live pmSIM experiments of three biological replicates for brown (BAT5, BAT13, BAT19) and two for white fat (WAT11a, WAT13a) were performed with a 1st isolation window and a +0.2 Th...
offset and acquired with a resolution of 120,000 at m/z 200. The heavy and light channels were multiplexed in a single scan. A maximum of 5 x 10^5 ions were collected in each channel with a maximum ion injection time of 120 ms for the light and heavy channel, respectively.

Data analysis of the pmSIM experiment was performed with the Skyline (Version 4.2.0.19009) and XCalibur (3.1.66.10) software suites. For data analysis light and heavy channel intensities for the EPDR1 peptide SYETWIGIYTVK were extracted from Skyline. Light channel intensities were normalized against the total background peptide MS1 intensity to take sample specific properties into account followed by normalization against the heavy channel. Fold change difference calculation was performed on the median white fat intensities.

**Western Blot Analysis on Cell Media**

For complement factor H, we validated proteomics data using western blot analysis on conditional media. The conditioned media was concentrated (3 different Brown adipocyte cell strains and 3 different White adipocyte cell strains) through two centrifugation rounds using an Amicon Ultra-4 3K and 10 K filter devices (Merck Millipore, USA). Purified proteins (FB Hycult HC2129, FH CompTech A137, Fl CompTech A138) were used as positive control. Growth media was used as negative control. Precision Plus Protein Blue (Bio-Rad, USA) was used as molecular weight (MW) marker. The CFH antibody was produced in-house by Prof. Peter Garred’s research group using mouse hybridomas and was used in a concentration of 1.8 μg/ml. The secondary antibody was Rabbit α-mouse HRP (Dako P0260 Lot# 00062101), utilized at a dilution of 1:10,000.

**Western Blot Analysis on Cell Lysate**

SiRNA mediated knockdown of EPDR1 was validated using western blot analysis on cell protein lysate. In short, the mature differentiated cells were washed twice with ice cold PBS and the lysed in lysis buffer containing 20 mM tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton-X, 2.5 mM Na₃P₂O₇, 1 mM α-glycerophosphate, 1mM Na₃VO₄, Complete Mini, Protease Inhibitor Cocktail. Lysates were centrifuged for 15 min at 13,000 g at 4°C. Protein concentration was determined using the Bio-Rad Protein (Bio-Rad, California, USA). 3.6 μg of protein lysate was loaded on Bis-Tris SDS-page gels and subject to electrophoresis, using iBright Prestained Protein ladder (Thermo Fisher Scientific) to determine MW of detected bands. Proteins were transferred to PVDF membranes by semi-dry transfer for 7 min with Pierce Power blot cassette. Membranes were blocked in FSG and incubated for 16 h with anti-EPDR1 at 1:1000 in 1% FSG (Thermo Fisher Scientific) or anti-α-Tubulin (Sigma-Aldrich) (1:1000 in 1% FSG). Bands were detected with IRDye secondary antibodies (LI-COR) at 1:5000 and visualized using the Odyssey Fc Imaging System (LI-COR).

**QUANTIFICATION AND STATISTICAL ANALYSIS**

Secretome data was collected from five separate brown adipocytes cultures derived from five different human donors and five separate white adipocytes cultures derived from five different human donors, thus representing biological replicates. Statistical analysis of proteomics data was performed using Perseus software (Tyanova et al., 2016). The details of the proteomics data analysis can be found in the STAR Methods in the section “Computational MS data analysis”. Statistical analyses of the rest of the experiments were performed with GraphPad Prism software. No methods were used to further determine whether the data met assumptions of the statistical approach. For the cell experiments in Figures 3E and 3H–3J, a representative brown fat culture was utilized and technical replicates (n=3) from independent experiments are presented. To account for a putative batch to batch variation, effects of EPDR1 knockdown and norepinephrine were assessed using a Mixed-effects analysis in Graphpad Prism 8, using repeated measurements for both EPDR1 knockdown and norepinephrine analysis. In case of a significant overall effect of EPDR1 knockdown, specific effects were assessed with Sidak’s multiple comparison’s test for which p-values are presented in the graphs. In the interpretation of the qPCR data, it should be considered that no correction for multiple testing was performed. All 21 genes measured was reported. Genes assessed in the data set presented in Figure 3 that were not significantly regulated are presented in Figures S2I and S2J using the same statistical approach. Additional statistical details, including exact value, description and exclusion of n as well as definition of center, and dispersion and precision measures, are specified in the figure legends. A p-value below 0.05 was considered significant.

**DATA AND CODE AVAILABILITY**

The assension number for the mass spectrometry proteomics data reported in this paper is ProteomeXchange: PXD008541. The data have been deposited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2019) partner repository.
Supplemental Information

Proteomics-Based Comparative Mapping of the Secretomes of Human Brown and White Adipocytes Reveals EPDR1 as a Novel Batokine

Figure S1: Relative UCP1 mRNA/PPIA mRNA in white and brown adipocytes. (A) UCP1 mRNA induction in white and brown adipocytes (n=11 and n=18, respectively). (B) UCP1 mRNA induction in white and brown adipocytes (n=10 and n=11, respectively). (C) UCP1 mRNA induction in white and brown adipocytes (n=11). (D) FABP4 mRNA/PPIA mRNA in white and brown adipocytes (n=9 and n=5, respectively). (E) FABP4 mRNA/PPIA mRNA in white and brown adipocytes (n=5).
Figure S1. Selection of cell cultures for secretomics experiment. Related to Figure 1.

Adipogenic precursor cells were isolated from the stromal vascular fraction of 21 biopsies obtained from the deep neck supraclavicular region (Jespersen et al., 2013). 18 of these cell cultures differentiated in vitro under the criteria of accumulating above 30% lipid droplets (as estimated using phase contrast microscopy). For comparison, we included white adipocytes derived from separate individuals while isolated and differentiated using the same protocols as used for the brown adipocytes. Prior to harvest, fully differentiated cells were stimulated for four hours with 10 µM norepinephrine (NE). The selected five brown adipocytes cultures are labelled black arrows throughout the graphs. A) Basal levels of UCP1 mRNA was measured using qPCR and cell cultures were ordered after expression. Seven of the “brown” cultures overlapped with the “white” in terms of UCP1 mRNA expression, while one “white” culture overlapped with the “brown”. We therefore excluded these cultures, leaving us with 11 brown adipocyte cultures and 10 white adipocyte cultures B) Fold change of UCP1 mRNA in response to NE, shown in the same order as in A. C) Fold change of UCP1 mRNA in response to NE, ordered after UCP1 mRNA induction. Two of the “brown” cultures overlapped in UCP1 fold change with the “white” adipocyte cultures and were therefore excluded. D) FABP4 mRNA levels were measured using qPCR and cell cultures are ordered in the same order as in C. Cells with as high UCP1 fold change and similar FABP4 mRNA expression were selected, which is shown with black arrows E) FABP4 mRNA levels in selected brown and white adipocytes. Data are relative gene expression levels for each individual sample, calculated using the delta delta CT method, using PPIA as an endogenous control.
**Figure S2**

**A** Histogram with imputation

![Histograms showing Log2 LFQ intensities for EPDR1](image)

**B** EPDR1 quantification in cell media

<table>
<thead>
<tr>
<th>BAT</th>
<th>LFQ (Log2)</th>
<th>WAT</th>
<th>LFQ (Log2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAT_woNE1</td>
<td>22.8825</td>
<td>WAT_woNE1</td>
<td>NaN</td>
</tr>
<tr>
<td>BAT_woNE2</td>
<td>22.7674</td>
<td>WAT_woNE2</td>
<td>NaN</td>
</tr>
<tr>
<td>BAT_woNE3</td>
<td>22.4275</td>
<td>WAT_woNE3</td>
<td>NaN</td>
</tr>
<tr>
<td>BAT_woNE4</td>
<td>NaN</td>
<td>WAT_woNE5</td>
<td>NaN</td>
</tr>
<tr>
<td>BAT_woNE5</td>
<td>22.6528</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**C** Volcano plot after imputation

![Volcano plot](image)

**D** Retention Time [min]

![Retention Time graph](image)

**E** Fold change

![Fold change graph](image)

**F** siEPDR1 siControl

![Gene expression image](image)

**G** Relative expression of EPDR1

![Expression of EPDR1](image)

**H** Relative expression of UCP1

![Expression of UCP1](image)

**I** Relative expression of DIO2

![Expression of DIO2](image)

**J** Relative expression of PPARGC1A

![Expression of PPARGC1A](image)
Figure S2. Identification and \textit{in vitro} characterization of EPDR1. Related to Figure 3.

A) LFQ values of EPDR1 in white versus brown adipocytes B) Imputation histograms. C) Volcano plot with EPDR1 annotated. D) Skyline output of the co-eluting heavy labeled EPDR1 peptide standard and the corresponding endogenous one across the brown (n=3) and two white (n=2) biological replicates. E) Results of the EPDR1 derived peptide SYETWIGIYTVK predictive multiplexed Selected Ion Monitoring (pmSIM) targeting experiment in white (N = 2) and brown fat (N = 3). The fold change was in both cases normalized against the median white endogenous peptide expression level. Brown fat shows a median 3.1-fold higher expression level of EPDR1 than white fat. F) Western blot analysis of EPDR1 protein in white and brown adipocytes with or without siRNA knockdown of \textit{EPDR1} (using a pool targeting four different sites of the \textit{EPDR1} mRNA transcript and a non-targeting siRNA control). G) Gene expression analysis of thermogenic marker genes following transfection with two single-sequenced siRNAs targeting separate sites on the \textit{EPDR1} mRNA transcript. A representative brown adipocyte culture was utilized and (n=3) represents three independent experiments. Data was analyzed using repeated measurements for siRNA transfection and norepinephrine stimulation and a Mixed effects analysis. In case of a significant (P<0.05) overall effect of EPDR1 knockdown, specific effects were assessed with Sidak’s multiple comparison’s test for which P values are presented in the graphs. Post-tests were performed comparing to the siRNA control samples. H) Representative image of mitochondrial (mitotracker) and lipid droplet (bodipy) staining in siEPDR1 or siControl transfected brown adipocytes (n=3). I-J) Relative gene expression of thermogenic and adipogenic marker genes unaltered following \textit{EPDR1} knockdown. A representative brown adipocyte culture was transfected in n=3 independent experiments. Data are mean presented as +/- SEM; *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001
Figure S3. Characterization and injections with human recombinant EPDR1. Related to Figure 4.

A) Coomassie blue staining of SDSPAGE, silver staining and liquid chromatography and mass spectrometry of EPDR1 isoform 1 protein. B) Calculated energy expenditure and Respiration Exchange Ratio (RER) following EPDR1 (n=8) or vehicle (n=8) injection in C57Bl/6NRj mice at thermoneutrality during the dark period. Unpaired t-tests of area under the curve (AUC) were performed to assess differences between groups. C) Relative mRNA expression of thermogenic markers UCP1, PRDM16, PGC-1α, PPARα and DIO2 following injection of recombinant EPDR1 with and without injection of CL 316,243 in female C57Bl/6NRj mice at thermoneutrality and during FDG-PET/CT scanning at general anesthesia (n=6-8/group as one mouse in the EPDR1 injection group was euthanized due to a paralyzed leg, and two mice in the EPDR1 + CL injection group were excluded due to bad injections. A two-way Anova with no matching was performed to test the effects of CL and EPDR1 injections, respectively. D) Calculated energy expenditure, locomotor activity and food intake of C57/Bl/6NRj mice on HFD in room temperature following daily injections of EPDR1 or vehicle injections for 21 days (n=8/group). Data are presented as mean +/- SEM, p-value *<0.5**<0.01***<0.001****<0.0001).
**Figure S4**

### A. EPDR1 transcript variant 1

- **Food intake**
  - **EPDR1 tv1/PPIA mRNA (A.U.)**
  - **siEPDR1**
  - **siControl**

### B. EPDR1 transcript variant 2

- **Food intake**
  - **EPDR1 tv2/PPIA mRNA (A.U.)**
  - **siEPDR1**
  - **siControl**

### C. EPDR1 transcript variants 1, 2, 3

- **Food intake**
  - **EPDR1 tv1, tv2, tv3/PPIA mRNA (A.U.)**
  - **siEPDR1**
  - **siControl**

### D. Relative expression of SFRP4

- **siEPDR1**
- **siControl**

### E. Relative expression of UCP1

- **siEPDR1**
- **siControl**

### F. Relative expression of DIO2

- **siEPDR1**
- **siControl**

### G. Relative expression of PPARGC1A

- **siEPDR1**
- **siControl**

### H. Energy expenditure

- **PBS**
- **SBSN**

### I. Food intake

- **PBS**
- **SBSN**

### J. Energy expenditure

- **PBS**
- **GM2A**

### K. Food intake

- **PBS**
- **GM2A**
Figure S4. Validation of EPDR1 siRNA knockdown and EPDR1 recombinant protein. Related to STAR methods.

Transcription variant specific qPCR primers for EPDR1 transcript 1 and 2, as well as a qPCR assay targeting transcript variant 1, 2 and 3 were designed and relative gene expression was measured to validate EPDR1 siRNA knockdown was assessed A) Relative mRNA expression of EPDR1 transcript variant 1 in white and brown adipocytes at day 1 and day 12 of differentiation following siRNA mediated knockdown of EPDR1 at day 0. B) Relative mRNA expression of EPDR1 transcript variant 2 in white and brown adipocytes at day 1 and day 12 of differentiation following siRNA mediated knockdown of EPDR1 at day 0. C) Relative mRNA expression of all EPDR1 transcript variants (1,2,3) in white and brown adipocytes at day 1 and day 12 of differentiation following siRNA mediated knockdown of EPDR1 at day 0. D) Relative mRNA expression SFRP4, transcribed from the opposite DNA strand of EPDR1 in brown adipocytes at day 12 of differentiation with or without siRNA knockdown of EPDR1. A-D were analyzed using paired t-tests to assess the effect of EPDR1 knockdown at each time point. E) Relative mRNA expression of UCP1 in brown and white adipocytes with or without NE stimulation following knockdown of EPDR1. F) Relative mRNA expression of DIO2 in brown and white adipocytes with or without NE stimulation following knockdown of EPDR1. G) Relative mRNA expression of PPARGC1A in brown and white adipocytes with or without NE stimulation following knockdown of EPDR1. E-G: Mixed effects analysis and Sidaks multiple comparison’s test for which P-values are presented in the graphs. H) Calculated energy expenditure following injection of SBSN during the dark phase. I) Food intake following injection of SBSN during the dark phase. J) Calculated energy expenditure following injection of GM2a during the dark phase. I) Food intake following injection of GM2a during the dark phase. Data are mean +/- SEM; *P<0.05, **P<0.01, ***P<0.001.
<table>
<thead>
<tr>
<th>Group</th>
<th>Sex (F:M)</th>
<th>Age (years)</th>
<th>BMI (kg/m²)</th>
<th>Fat%</th>
<th>P-EPDR1 (ng/ml)</th>
<th>UCP1 mRNA (A.U)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPDR1-</td>
<td>6:1</td>
<td>56 (29 -74)</td>
<td>27 (20 – 38)</td>
<td>40.3</td>
<td>N.D.</td>
<td>31.9 (2.1 -11,416.8)</td>
</tr>
<tr>
<td>EPDR1+</td>
<td>17:6</td>
<td>48 (23 – 56)</td>
<td>30 (18 – 38)</td>
<td>38.7</td>
<td>58.0</td>
<td>5724.5 (15.8 – 19,178.8)</td>
</tr>
</tbody>
</table>

Values are median and range. BMI = Body mass index, N.D. = not detectable
Table S5. Primers, probes and short interfering RNAs. Related to STAR Methods.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Taqman assay ID</th>
<th>Forward primer (5'-3')</th>
<th>Reverse primer (5'-3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>hADIPOQ</td>
<td>Hs00962373_m1</td>
<td>CTGGTGAGAAAGGTAGAAAG</td>
<td>GITTCCACGGATGTCTCCTTTAG</td>
</tr>
<tr>
<td>hCIDEA</td>
<td>Hs00176484_m1</td>
<td>TCAAGGGCCTGCTGAGAGTCT</td>
<td>AAACGTCCGCGTACCTGGGC</td>
</tr>
<tr>
<td>hCITED1</td>
<td>Hs00160173_m1</td>
<td>GAGCCTGACATGTTGTC</td>
<td>CACGGAGCTCATCCTGTTT</td>
</tr>
<tr>
<td>hCKMT1</td>
<td>Hs00180066_m1</td>
<td>TTGAGGAGACCTATGAGGTCT</td>
<td>CAGATTAGGACCGAGAAAG</td>
</tr>
<tr>
<td>hCKMT2</td>
<td>Hs00184772_m1</td>
<td>TGGTCGATCAGAGGTTGAGC</td>
<td>CTGTGCACTCAGCAAGACAG</td>
</tr>
<tr>
<td>hCOL1A2</td>
<td>Mm00515664_m1</td>
<td>TGAAACCTGGATTGGCATATAC</td>
<td>AGTGTGCACTCAGCAAGACAG</td>
</tr>
<tr>
<td>hFABP4</td>
<td>Mm00515664_m1</td>
<td>GAGAGGAAGGCGCTGATCC</td>
<td>TGAGCCTGAGCTCAATGCTGA</td>
</tr>
<tr>
<td>hGLUT4</td>
<td>Mm00447183_m1</td>
<td>CAGAGGAGCCGCTGATCC</td>
<td>TGAGCCTGAGCTCAATGCTGA</td>
</tr>
<tr>
<td>hLPL</td>
<td>Mm00440939_m1</td>
<td>GACGCCACCGGCCAGAAAAC</td>
<td>TGACACCCCCACATCTAAGGT</td>
</tr>
<tr>
<td>hPFHB</td>
<td>Mm00712556_m1</td>
<td>TCTCCCTACGAGGGGCTCA</td>
<td>AGGTGTCATTCTCGAGGAA</td>
</tr>
<tr>
<td>hPDGFr</td>
<td>Mm01244861_m1</td>
<td>TGAAACCTGGATTGGCATATAC</td>
<td>AGTGTGCACTCAGCAAGACAG</td>
</tr>
<tr>
<td>hSCD</td>
<td>Mm00160173_m1</td>
<td>TCTTTGAATCTGAGATTTCTCA</td>
<td>GACACCCCCACATCTAAGGT</td>
</tr>
<tr>
<td>mADIPQ</td>
<td>Mm00515664_m1</td>
<td>CAGAGGAGCCGCTGATCC</td>
<td>TGAGCCTGAGCTCAATGCTGA</td>
</tr>
<tr>
<td>mCIDEA</td>
<td>Mm00447183_m1</td>
<td>CAGAGGAGCCGCTGATCC</td>
<td>TGAGCCTGAGCTCAATGCTGA</td>
</tr>
<tr>
<td>mCITED1</td>
<td>Mm00440939_m1</td>
<td>CAGAGGAGCCGCTGATCC</td>
<td>TGAGCCTGAGCTCAATGCTGA</td>
</tr>
<tr>
<td>mCOL1A2</td>
<td>Mm00712556_m1</td>
<td>TCTTTGAATCTGAGATTTCTCA</td>
<td>GACACCCCCACATCTAAGGT</td>
</tr>
<tr>
<td>mFABP4</td>
<td>Mm01244861_m1</td>
<td>TCTTTGAATCTGAGATTTCTCA</td>
<td>GACACCCCCACATCTAAGGT</td>
</tr>
<tr>
<td>mGLUT4</td>
<td>Mm00712556_m1</td>
<td>TCTTTGAATCTGAGATTTCTCA</td>
<td>GACACCCCCACATCTAAGGT</td>
</tr>
<tr>
<td>mLASP1</td>
<td>Mm00515664_m1</td>
<td>CAGAGGAGCCGCTGATCC</td>
<td>TGAGCCTGAGCTCAATGCTGA</td>
</tr>
<tr>
<td>mPRDM16</td>
<td>Mm00160173_m1</td>
<td>TCTTTGAATCTGAGATTTCTCA</td>
<td>GACACCCCCACATCTAAGGT</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Short interfering RNAs</th>
<th>Assay Id</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-targeting Pool</td>
<td>D-001810-10</td>
</tr>
<tr>
<td>hEPDR1 (pool of 4)</td>
<td>L-013378-01</td>
</tr>
<tr>
<td>hEPDR1 (Individual)</td>
<td>J-013378-09</td>
</tr>
<tr>
<td>hEPDR1 (Individual)</td>
<td>J-013378-10</td>
</tr>
</tbody>
</table>